^
Association details:
| Biomarker: | CD20 expression |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bortezomib and Rituximab in De Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukaemia: Updated 3-Year Results
Published date:
09/21/2022
Excerpt:
On longer follow up (median follow up 38months), 3-year EFS and OS rates were 75.6% (95% CI 62.3-91.9%), and 75.6% (95% CI 62.3-91.9%) respectively. 3-year rates of EFS based on post-induction (week 4) MRD status was 55.6% (31-99.7%) in MRD positive group compared with 86.1% (72.7-100%) in MRD negative group. 3-year rates of OS based on EOI MRD status was 55.6% (31-99.7%) in MRD positive group compared with 86.1% (72.7-100%) in MRD negative group. On longer follow-up, the activity of the combination of bortezomib and rituximab is maintained without any new safety concerns.
Secondary therapy:
bortezomib
Source:
Title:
1024 Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study
Published date:
11/04/2020
Excerpt:
After a median follow up of 18 months, event-free survival and overall survival were 81.8% and 84.7%, respectively....The combination of bortezomib, rituximab and paediatric-inspired ALL regimen is active and well tolerated in in de-novo CD20 positive Ph-negative precursor B-ALL.
Secondary therapy:
bortezomib
